San Antonio, TXNCT01906385Now EnrollingIRB Ready

Brain Cancer Clinical Trial in San Antonio, TX

Access cutting-edge brain cancer treatment through this phase 1/2 clinical trial at a research site in San Antonio. Study-provided care at no cost to qualified participants.

Sponsored by Plus Therapeutics

Quick Self-Assessment

See if you qualify for this San Antonio location

Preparing your pre-screening questions…

Expert Care in San Antonio

Access brain cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related brain cancer treatment provided free

Apply for This San Antonio Location

Check if you qualify for this brain cancer clinical trial in San Antonio, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to San Antonio

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit San Antonio site if eligible
  4. 4Begin participation

About This Brain Cancer Study in San Antonio

This is a multi-center, sequential cohort, open-label, volume and dose escalation study of the safety, tolerability, and distribution of 186RNL given by convection enhanced delivery to patients with recurrent or progressive malignant glioma after standard surgical, radiation, and/or chemotherapy treatment. The study uses a modified Fibonacci dose escalation, followed by an expansion at the maximum tolerated dose (MTD) to determine efficacy. The starting absorbed dose is 1mCi in a volume of 0.660

Sponsor: Plus Therapeutics

Who Can Participate

Inclusion Criteria

At least 18 years of age.
Ability to understand the purposes and risks of the study and has signed a written informed consent form approved by the investigator's IRB/Ethics Committee.
Histologically confirmed Grade III/IV recurrent Glioma (following 2021 WHO CNS5 glioma nomenclature, e.g., Astrocytoma, IDH-mutant grade 3 or 4; Glioblastoma, IDH-wildtype grade 4).
Progression by RANO criteria or other clinically accepted neurooncology evaluation, following standard treatment options with known survival benefit for any recurrence (e.g., surgery, temozolomide, radiation, and tumor treating fields). Patient may be included in study if medically unable or unwilling to follow standard treatment options for any recurrence.
Patients who receive treatment with antiepileptic medications must have a two-week history of stable dose of antiepileptic without seizures prior to study start (dosing).
Patients with corticosteroid requirements to control cerebral edema must be maintained at a stable or decreasing dose for a minimum of two weeks without progression of clinical symptoms prior to study start (dosing).
Patients with Grade III/IV Glioma (following 2021 WHO CNS5 glioma nomenclature, e.g., Astrocytoma, IDH-mutant grade 3 or 4; Glioblastoma, IDH-wildtype grade 4) which falls within the treatment field volume.
ECOG performance status of 0 to 2; Karnofsky Performance Status ≥ 60.
Life expectancy of at least 2 months.
Acceptable liver function:
Bilirubin ≤ 1.5 times upper limit of normal
AST (SGOT) and ALT (SGPT) ≤ 3.0 times upper limit of normal (ULN)
Acceptable renal function: a. Serum creatinine ≤1.5xULN
Acceptable hematologic status (without hematologic support):
ANC ≥1000 cells/uL
Platelet count ≥100,000/uL
Hemoglobin ≥9.0 g/dL
All women of childbearing potential must have a negative serum pregnancy test and male and female subjects must agree to use effective means of contraception (for example, surgical sterilization or the use of barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an IUD) with their partner from entry into the study through 6 months after the last dose.

Exclusion Criteria

The subject has evidence of acute intracranial or intratumoral hemorrhage either by magnetic resonance imaging (MRI) or computerized tomography (CT) scan. Subjects with resolving hemorrhage changes, punctate hemorrhage, or hemosiderin are eligible.
The subject is unable or contraindicated to undergo MRI scan (e.g., has pacemaker or medically unstable).
The subject has not recovered to CTCAE v4.0 Grade ≤1 from AEs (except alopecia, anemia, and lymphopenia) due to antineoplastic agents, investigational drugs, or other medications that were administered prior to study.
The subject is pregnant or breast-feeding.
The subject has serious intercurrent illness, as determined by the treating physician, which would compromise either patient safety or study outcomes such as:
hypertension (two or more blood pressure readings performed at screening of \>150 mmHg systolic or \>100 mmHg diastolic) despite optimal treatment
active medically significant infection unresponsive to antibiotics (e.g., non- healing wound, ulcer), uncontrolled systemic infection, or bone fracture
clinically significant cardiac arrhythmias not controlled by appropriate medications
untreated hypothyroidism
symptomatic congestive heart failure or unstable angina pectoris within 3 months prior to study drug
myocardial infarction, stroke, or transient ischemic attack within 6 months prior to study drug
known active malignancy (other than glioma) except non-melanoma skin cancer or carcinoma in-situ in the cervix unless PI determines it would not impact patient safety or efficacy determinations
The subject has inherited bleeding diathesis or coagulopathy with the risk of bleeding.
The subject has received any of the following prior anticancer therapy:
Prior treatment with Bevacizumab
Non-standard radiation therapy such as brachytherapy, systemic radioisotope therapy, or intra-operative radiotherapy (IORT) to the target site
Radiation therapy within 12 weeks of screening
Systemic therapy (including investigational agents and small-molecule kinase inhibitors) or non-cytotoxic hormonal therapy (e.g., tamoxifen) within 14 days or 5 half-lives, whichever is shorter, prior to study start (dosing)
Biologic agents (antibodies, immune modulators, vaccines, cytokines) within 21 days prior to study start (dosing)
Nitrosoureas or mitomycin C within 42 days, or metronomic/protracted low- dose chemotherapy within 14 days, or other cytotoxic chemotherapy within 28 days, prior to study start (dosing)
Prior treatment with carmustine wafers
Patients who are currently receiving any other investigational agents and/or who have received an investigational agent in 28 days prior to study start (dosing)
Multifocal progression or involvement of the leptomeninges.
Psychiatric illness/social situations that would limit compliance with the study requirements
Infratentorial disease
The subject has a tumor located within 1-2 cm of a ventricle AND it is determined by the surgeon, PI, and sponsor to be a risk for drug extravasation to the subarachnoid space if given catheter placement and drug administration.
Phase 2 only: The subject should have a tumor volume of ≤20 cm3 to be included in the Phase 2 portion of the study. Subjects with tumor volumes of greater than 20 cm3 are excluded from the Phase 2 portion of the study.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in San Antonio?

Yes, this clinical trial (NCT01906385) has an active research site in San Antonio, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Brain Cancer Treatment Options in San Antonio, TX

If you're searching for brain cancer treatment options in San Antonio, TX, this clinical trial (NCT01906385) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our San Antonio research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced brain cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all brain cancer clinical trials near you to find additional studies recruiting in your area.

More Brain Cancer Trials in San Antonio, TX

See all brain cancer clinical trials recruiting in San Antonio — not just this study.

Browse Brain Cancer Trials in San Antonio →

Browse More Trials by Condition

Brain Cancer TrialsRheumatoid Arthritis TrialsAll Conditions →

Ready to Join in San Antonio?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · San Antonio, TX